
TY  - JOUR
TI  - Abstracts of the 23rd International Conference on Pharmacoepidemiology & Therapeutic Risk Management
JO  - Pharmacoepidemiology and Drug Safety
JA  - Pharmacoepidem. Drug Safe.
VL  - 16
IS  - S2
SN  - 1053-8569
UR  - https://doi.org/10.1002/pds.1461
DO  - doi:10.1002/pds.1461
SP  - S1
EP  - S274
PY  - 2007
ER  - 

TY  - JOUR
TI  - Poster Abstracts
JO  - Colorectal Disease
JA  - Colorectal Dis
VL  - 18
IS  - S1
SN  - 1462-8910
UR  - https://doi.org/10.1111/codi.13445
DO  - doi:10.1111/codi.13445
SP  - 44
EP  - 125
PY  - 2016
ER  - 

TY  - JOUR
TI  - Scientific Section
JO  - Transfusion
VL  - 45
IS  - s3
SN  - 0041-1132
UR  - https://doi.org/10.1111/j.1537-2995.2005.00629_1.x
DO  - doi:10.1111/j.1537-2995.2005.00629_1.x
SP  - 1A
EP  - 151A
PY  - 2005
ER  - 

TY  - JOUR
TI  - ASPC Abstracts Supplement
JO  - Clinical Cardiology
JA  - Clin Cardiol
VL  - 42
IS  - S2
SN  - 0160-9289
UR  - https://doi.org/10.1002/clc.23281
DO  - doi:10.1002/clc.23281
SP  - S36
EP  - S49
PY  - 2019
ER  - 

TY  - JOUR
TI  - Thirty-Sixth Annual Meeting American College of Clinical Pharmacology September 9â€“11, 2007 San Francisco, California
JO  - The Journal of Clinical Pharmacology
VL  - 47
IS  - 9
SN  - 0091-2700
UR  - https://doi.org/10.1177/0091270007305480
DO  - doi:10.1177/0091270007305480
SP  - 1183
EP  - 1211
PY  - 2007
ER  - 

TY  - JOUR
TI  - Paper Abstracts
JO  - Journal of the American Geriatrics Society
VL  - 52
IS  - s1
SN  - 0002-8614
UR  - https://doi.org/10.1111/j.1532-5415.2004.05204002.x
DO  - doi:10.1111/j.1532-5415.2004.05204002.x
SP  - S1
EP  - S218
PY  - 2004
ER  - 

TY  - JOUR
TI  - Abstracts
JO  - Anaesthesia
JA  - Anaesthesia
VL  - 71
IS  - S2
SN  - 0003-2409
UR  - https://doi.org/10.1111/anae.13350
DO  - doi:10.1111/anae.13350
SP  - 8
EP  - 88
PY  - 2016
ER  - 

TY  - JOUR
TI  - Administrative Abstracts
JO  - Transfusion
JA  - Transfusion
VL  - 53
IS  - S2
SN  - 0041-1132
UR  - https://doi.org/10.1111/trf.12401_2
DO  - doi:10.1111/trf.12401_2
SP  - 219
EP  - 278A
PY  - 2013
ER  - 

TY  - JOUR
AU  - Rosenthal, Liana S.
AU  - Drake, Daniel
AU  - Alcalay, Roy N.
AU  - Babcock, Debra
AU  - Bowman, F. DuBois
AU  - Chen-Plotkin, Alice
AU  - Dawson, Ted M.
AU  - Dewey Jr., Richard B.
AU  - German, Dwight C.
AU  - Huang, Xuemei
AU  - Landin, Barry
AU  - McAuliffe, Matthew
AU  - Petyuk, Vladislav A.
AU  - Scherzer, Clemens R.
AU  - Hillaire-Clarke, Coryse St.
AU  - Sieber, Beth-Anne
AU  - Sutherland, Margaret
AU  - Tarn, Chi
AU  - West, Andrew
AU  - Vaillancourt, David
AU  - Zhang, Jing
AU  - Gwinn, Katrina
AU  - on behalf of the PDBP consortium
TI  - The NINDS Parkinson's disease biomarkers program
JO  - Movement Disorders
JA  - Mov Disord.
VL  - 31
IS  - 6
SN  - 0885-3185
UR  - https://doi.org/10.1002/mds.26438
DO  - doi:10.1002/mds.26438
SP  - 915
EP  - 923
KW  - Parkinsonism
KW  - disease-modifying strategies
KW  - biofluids
KW  - data management
PY  - 2016
AB  - Abstract Background Neuroprotection for Parkinson's disease (PD) remains elusive. Biomarkers hold the promise of removing roadblocks to therapy development. The National Institute of Neurological Disorders and Stroke has therefore established the Parkinson's Disease Biomarkers Program to promote discovery of PD biomarkers for use in phase II and III clinical trials. Methods Using a novel consortium design, the Parkinson's Disease Biomarker Program is focused on the development of clinical and laboratory-based biomarkers for PD diagnosis, progression, and prognosis. Standardized operating procedures and pooled reference samples were created to allow cross-project comparisons and assessment of batch effects. A web-based Data Management Resource facilitates rapid sharing of data and biosamples across the research community for additional biomarker projects. Results Eleven consortium projects are ongoing, seven of which recruit participants and obtain biosamples. As of October 2014, 1,082 participants have enrolled (620 PD, 101 with other causes of parkinsonism, 23 essential tremor, and 338 controls), 1,040 of whom have at least one biosample. Six thousand eight hundred ninety-eight total biosamples are available from baseline, 6-, 12-, and 18-month visits: 1,006 DNA, 1,661 RNA, 1,419 whole blood, 1,382 plasma, 1,200 serum, and 230 cerebrospinal fluid (CSF). Quality control analysis of plasma, serum, and CSF samples indicates that almost all samples are high quality (24 of 2,812 samples exceed acceptable hemoglobin levels). Conclusions By making samples and data widely available, using stringent operating procedures based on existing standards, hypothesis testing for biomarker discovery, and providing a resource that complements existing programs, the Parkinson's Disease Biomarker Program will accelerate the pace of PD biomarker research. ? 2015 International Parkinson and Movement Disorder Society
ER  - 

TY  - JOUR
AU  - Holers, V. Michael
TI  - The spectrum of complement alternative pathway-mediated diseases
JO  - Immunological Reviews
VL  - 223
IS  - 1
SN  - 0105-2896
UR  - https://doi.org/10.1111/j.1600-065X.2008.00641.x
DO  - doi:10.1111/j.1600-065X.2008.00641.x
SP  - 300
EP  - 316
KW  - complement
KW  - inhibitors
KW  - complement deficiency
KW  - genetics
PY  - 2008
AB  - Summary: The complement system has once again come into prominence in the therapeutic development arena. The recent approval of an inhibitory monoclonal antibody, eculizumab, which is directed against complement component C5 for the disease paroxysmal nocturnal hemoglobinuria has provided the initial validation of this system as a therapeutic target. Preclinical studies using animal models and human-derived samples demonstrate that inhibition of complement ameliorates many inflammatory and autoimmune disease manifestations. Major efforts continue to define the most optimal means to block complement activation in a cost-effective manner. Because the system is initiated through three pathways and generates at least six immunoregulatory and pro-inflammatory mediators, there is substantial complexity to this problem. One pathway, designated the alternative pathway, has recently been shown to play a particularly important role in preclinical disease models. Further evidence of the importance of the alternative pathway has been provided by studies of human diseases, where mutations or dysfunctional polymorphisms that promote activation of this pathway are highly associated with the diseases atypical hemolytic uremic syndrome, dense deposit disease, and age-related macular degeneration. This article reviews evidence in support of the essential role of the alternative pathway in the generation of tissue injury and the rationale for development of therapies that modulate its activity.
ER  - 

TY  - JOUR
TI  - 55th ANNUAL MEETING AND EXHIBITION
JO  - Medical Physics
JA  - Med. Phys.
VL  - 40
IS  - 6Part33
SN  - 0094-2405
UR  - https://doi.org/10.1002/j.2473-4209.2013.tb00217.x
DO  - doi:10.1002/j.2473-4209.2013.tb00217.x
SP  - 1
EP  - 579
PY  - 2013
ER  - 

TY  - JOUR
AU  - Pizzutiello, R
AU  - Svatos, M
TI  - SU-A-BRE-01: AAPM Medical Physics Student Meeting
JO  - Medical Physics
JA  - Med. Phys.
VL  - 41
IS  - 6Part2
SN  - 0094-2405
UR  - https://doi.org/10.1118/1.4889690
DO  - doi:10.1118/1.4889690
SP  - 89
EP  - 89
KW  - Medical physics
KW  - Medical physicists
KW  - Environmental impacts
PY  - 2014
AB  - The purpose of this meeting is to emphasize entrepreneurship and opportunities in industry as a valuable part of our profession, bringing the benefits of new ideas and techniques generated by the basic scientists to the broad patient population. Thinking outside the traditional ?clinical Medical Physics box?, there are a variety of ways that individuals can use their medical physics training/experience in entrepreneurial endeavors. Whether as an individual, a small group of medical physicists, or part of an industry (corporate) environment, the speakers will explore how current students and trainees can make a veritable impact to our profession in a non-clinical setting. Our distinguished speakers will also be happy to answer general questions from the audience.
ER  - 

TY  - JOUR
TI  - Lunchtime Poster Presentations
JO  - Colorectal Disease
VL  - 12
IS  - s3
SN  - 1462-8910
UR  - https://doi.org/10.1111/j.1463-1318.2010.02366.x
DO  - doi:10.1111/j.1463-1318.2010.02366.x
SP  - 15
EP  - 27
PY  - 2010
ER  - 

TY  - JOUR
TI  - American Society for Clinical Pharmacology and Therapeutics
JO  - Clinical Pharmacology & Therapeutics
JA  - Clin. Pharmacol. Ther.
VL  - 99
IS  - S1
SN  - 0009-9236
UR  - https://doi.org/10.1002/cpt.310
DO  - doi:10.1002/cpt.310
SP  - S5
EP  - S107
PY  - 2016
ER  - 

TY  - JOUR
TI  - Orals
JO  - Transplant International
JA  - Transpl Int
VL  - 28
IS  - S4
SN  - 0934-0874
UR  - https://doi.org/10.1111/tri.12700
DO  - doi:10.1111/tri.12700
SP  - 1
EP  - 133
PY  - 2015
ER  - 

TY  - JOUR
TI  - Wednesday, 2 September 2009 - Parallel Sessions 37-42
JO  - Transplant International
VL  - 22
IS  - s2
SN  - 0934-0874
UR  - https://doi.org/10.1111/j.1432-2277.2009.00961.x
DO  - doi:10.1111/j.1432-2277.2009.00961.x
SP  - 82
EP  - 92
PY  - 2009
ER  - 

TY  - JOUR
TI  - Abstract Journal General Surgery
JO  - ANZ Journal of Surgery
JA  - ANZ J Surg
VL  - 87
IS  - S1
SN  - 1445-1433
UR  - https://doi.org/10.1111/ans.13993
DO  - doi:10.1111/ans.13993
SP  - 41
EP  - 60
PY  - 2017
ER  - 

TY  - JOUR
TI  - 2013 AAPM Annual Meeting Program
JO  - Medical Physics
JA  - Med. Phys.
VL  - 40
IS  - 6Part33
SN  - 0094-2405
UR  - https://doi.org/10.1002/j.2473-4209.2013.tb00215.x
DO  - doi:10.1002/j.2473-4209.2013.tb00215.x
SP  - 82
EP  - 553
PY  - 2013
ER  - 

TY  - JOUR
TI  - Symposia and Oral Presentations
JO  - Clinical Microbiology and Infection
VL  - 18
IS  - s3
SN  - 1198-743X
UR  - https://doi.org/10.1111/j.1469-0691.2012.03801.x
DO  - doi:10.1111/j.1469-0691.2012.03801.x
SP  - 1
EP  - 113
PY  - 2012
ER  - 

TY  - JOUR
TI  - Monday 21st July 2008
JO  - International Journal of Psychology
JA  - International Journal of Psychology
VL  - 43
IS  - 3-4
SN  - 0020-7594
UR  - https://doi.org/10.1080/00207594.2008.10108483
DO  - doi:10.1080/00207594.2008.10108483
SP  - 1
EP  - 167
PY  - 2008
ER  - 
